News
BioCardia Narrows Loss in Fiscal Q2
BioCardia (NASDAQ:BCDA), a clinical-stage cell therapy company focused on treatments for heart disease, released its financial results for the second quarter of 2025 on August 11, 2025. The company
Agenus Posts 48% Q2 Revenue Miss
Agenus (NASDAQ:AGEN), a clinical-stage biotechnology company focused on developing cancer immunotherapies, reported its second quarter 2025 earnings on August 11, 2025. The company's revenue (GAAP)
Harvard Bioscience Tops Q2 Revenue Views
Harvard Bioscience (NASDAQ:HBIO), a provider of specialized laboratory technologies for biomedical and life sciences research, released its financial results for the second quarter of fiscal 2025 on
RadNet Posts Record Q2 Revenue Up 8%
RadNet (NASDAQ:RDNT), a major operator of outpatient diagnostic imaging centers, published its second quarter 2025 results on August 11, 2025. The company reported record revenue of $498.2 million
AppLovin Shares Jump as Revenue Continues to Surge. Is It Too Late to Buy the Stock?
AppLovin (NASDAQ: APP) once again held up to the short-seller scrutiny it's been under, with yet another quarter of surging revenue and profitability growth. The stock is now up more than 500% over
EQS-News: Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction
Meet the 7.3% Yield Dividend Stock That Could Soar in 2026
It's been a tough stretch for pharmaceutical giant Pfizer (NYSE: PFE). The company enjoyed a vaccine windfall during the COVID-19 pandemic, but revenue and profits cratered as the pandemic eased and
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
The S&P 500 has a miserly yield of 1.2%. The average healthcare stock's yield is about 1.8%. Compared to that, Merck's (NYSE: MRK) roughly 4% yield is highly attractive. And LTC Properties' (NYSE:
3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August
If you are looking at healthcare stocks for dividend ideas in August, don't get too caught up on the sector's low 1.8% dividend yield. You can do much better than that without having to take on huge
AMD Shares Sink Despite Strong Growth. Is It Time to Buy the Dip?
After being a laggard to start the year, Advanced Micro Devices (NASDAQ: AMD) has rallied strongly during the summer. However, its shares took a dip following the announcement of its second-quarter
3 Stocks Retirees Should Absolutely Love
Priorities change as you enter new seasons of life. That's especially true for your retirement years. And the changing priorities can include what you want from your investments. Income usually
Why Nektar Therapeutics Stock Popped 6% on Friday
Biotech Nektar Therapeutics (NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for
Parks America Posts Q3 Profit Surge
Parks! America (OTC:PRKA), an operator of three regional safari parks in Georgia, Missouri, and Texas, reported earnings for its fiscal third quarter on August 8, 2025, with income before income
5 Stocks to Buy on a Pullback
Valuations have been a concern for many investors across the board, but as investors, we should constantly be putting in the work so that we are prepared for when opportunities persist.
In today's
Should You Buy AMD Stock on the Dip?
Advanced Micro Devices (NASDAQ: AMD) reported quarterly financial results that disappointed stock market investors.
*Stock prices used were the afternoon prices of Aug. 4, 2025. The video was
Here's Why I Remain Bullish on AMD Despite the Dip After Earnings
In this video, I will go over Advanced Micro Devices' (NASDAQ: AMD) earnings report and explain what the market missed and why I remain extremely bullish. Watch the short video to learn more
Why Is Everyone Talking About UnitedHealth Group Stock?
UnitedHealth (NYSE: UNH) stock is trading near its 52-week low.
*Stock prices used were the afternoon prices of Aug. 4, 2025. The video was published on Aug. 6, 2025.
Source Fool.c
Opinion: This Was the Last Mediocre Quarter for AMD Before the AI Story Begins
In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD). To learn more, check out the short video, consider subscribing, and click the special offer link below.
Nektar (NKTR) Q2 Revenue Falls 52%
Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biopharmaceutical company focusing on immunology and oncology drug development, reported its latest financial results on August 7, 2025, for the
MicroVision (MVIS) Q2 Revenue Drops 92%
MicroVision (NASDAQ:MVIS), a company specializing in lidar (light detection and ranging) sensor hardware and integrated perception software for automotive, industrial, and defense markets, reported
Coherus (CHRS) Q2 Revenue Jumps 10%
Coherus Oncology (NASDAQ:CHRS), a biotechnology company focused on developing and commercializing innovative immuno-oncology therapies, reported earnings for Q2 2025 on August 7, 2025. The results
CytomX (CTMX) Q2 Revenue Drops 26%
CytomX Therapeutics (NASDAQ:CTMX), a biotechnology company focused on developing targeted oncology therapies, reported its second quarter 2025 results on August 7, 2025. In the period, the most
Natera (NTRA) Q2 Revenue Jumps 32%
Natera (NASDAQ:NTRA), a leader in genetic testing across oncology, women's health, and organ health, reported its earnings for Q2 2025 on August 7, 2025. The most significant news was a 32.2%
ORGO Sales Drop 23%
Organogenesis (NASDAQ:ORGO), a regenerative medicine company specializing in advanced wound care and surgical and sports medicine products, reported Q2 2025 results on August 7, 2025. The standout
Trupanion (TRUP) Q2 Profit Surges 124%
Trupanion (NASDAQ:TRUP), a provider of pet health insurance, reported results for the second quarter of fiscal 2025 on August 7, 2025. The company surprised analysts with diluted earnings per share